Exact Mass: 418.2484

Exact Mass Matches: 418.2484

Found 172 metabolites which its exact mass value is equals to given mass value 418.2484, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

4,4-(Diphenylethenylidene)bis[N,N-dimethylbenzenamine]

C30H30N2 (418.2409)

CPA(18:1(11Z)/0:0)

(2-hydroxy-2-oxo-1,3,2$l^{5}-dioxaphospholan-4-yl)methyl (11Z)-octadec-11-enoate

C21H39O6P (418.2484)

cPA(18:1(11Z)/0:0) is a cyclic phosphatidic acid or cyclic lysophosphatidic acid. It is a glycerophospholipid in which a cyclic phosphate moiety occupies two glycerol substitution sites. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1). Fatty acids containing 16 and 18 carbons are the most common. Cyclic phosphatidic acids have been detected in a wide range of organisms including humans, especially in the brain but also in serum (at a concentration of 10-7M). cPAs have a cyclic phosphate at the sn-2 and sn-3 positions of the glycerol carbons, and this structure is absolutely necessary for their activities. In particular, it is found in tissues subject to injury, and while it may have some similar signalling functions to lysophosphatidic acid per se, it also has some quite distinct biological activities. For example, cyclic phosphatidic acid is known to be a specific inhibitor of DNA polymerase alpha. It has an appreciable effect on the inhibition of cancer cell invasion and metastasis. [HMDB] cPA(18:1(11Z)/0:0) is a cyclic phosphatidic acid or cyclic lysophosphatidic acid. It is a glycerophospholipid in which a cyclic phosphate moiety occupies two glycerol substitution sites. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1). Fatty acids containing 16 and 18 carbons are the most common. Cyclic phosphatidic acids have been detected in a wide range of organisms including humans, especially in the brain but also in serum (at a concentration of 10-7M). cPAs have a cyclic phosphate at the sn-2 and sn-3 positions of the glycerol carbons, and this structure is absolutely necessary for their activities. In particular, it is found in tissues subject to injury, and while it may have some similar signalling functions to lysophosphatidic acid per se, it also has some quite distinct biological activities. For example, cyclic phosphatidic acid is known to be a specific inhibitor of DNA polymerase alpha. It has an appreciable effect on the inhibition of cancer cell invasion and metastasis.

CPA(18:1(9Z)/0:0)

(2-Hydroxy-2-oxo-1,3,2λ⁵-dioxaphospholan-4-yl)methyl (9Z)-octadec-9-enoic acid

C21H39O6P (418.2484)

cPA(18:1(9Z)/0:0) is a cyclic phosphatidic acid or cyclic lysophosphatidic acid. It is a glycerophospholipid in which a cyclic phosphate moiety occupies two glycerol substitution sites. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1). Fatty acids containing 16 and 18 carbons are the most common. Cyclic phosphatidic acids have been detected in a wide range of organisms including humans, especially in the brain but also in serum (at a concentration of 10-7M). cPAs have a cyclic phosphate at the sn-2 and sn-3 positions of the glycerol carbons, and this structure is absolutely necessary for their activities. In particular, it is found in tissues subject to injury, and while it may have some similar signalling functions to lysophosphatidic acid per se, it also has some quite distinct biological activities. For example, cyclic phosphatidic acid is known to be a specific inhibitor of DNA polymerase alpha. It has an appreciable effect on the inhibition of cancer cell invasion and metastasis. [HMDB] cPA(18:1(9Z)/0:0) is a cyclic phosphatidic acid or cyclic lysophosphatidic acid. It is a glycerophospholipid in which a cyclic phosphate moiety occupies two glycerol substitution sites. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1). Fatty acids containing 16 and 18 carbons are the most common. Cyclic phosphatidic acids have been detected in a wide range of organisms including humans, especially in the brain but also in serum (at a concentration of 10-7M). cPAs have a cyclic phosphate at the sn-2 and sn-3 positions of the glycerol carbons, and this structure is absolutely necessary for their activities. In particular, it is found in tissues subject to injury, and while it may have some similar signalling functions to lysophosphatidic acid per se, it also has some quite distinct biological activities. For example, cyclic phosphatidic acid is known to be a specific inhibitor of DNA polymerase alpha. It has an appreciable effect on the inhibition of cancer cell invasion and metastasis.

MFA

methyl (10R,13S,17S)-17-benzoyl-10,13-dimethyl-2,7,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-3-carboxylate

C28H34O3 (418.2508)

Mfa is practically insoluble (in water) and an extremely weak acidic compound (based on its pKa). Mfa can be found in french plantain, which makes mfa a potential biomarker for the consumption of this food product. MFA may refer to: .

Icariside C3

C21H38O8 (418.2567)

Icariside C2

C21H38O8 (418.2567)

Ophiopogonoside A

(2R,3R,4S,5S,6R)-2-[[(1R,2S,4aR,5R,8S,8aR)-5,8-dihydroxy-4a,8-dimethyl-2-propan-2-yl-1,2,3,4,5,6,7,8a-octahydronaphthalen-1-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol

C21H38O8 (418.2567)

Ophiopogonoside A is a natural product found in Ophiopogon japonicus and Liriope muscari with data available.

(2E,4E,6E)-cyclo-[(NMe-L-Ala)-L-Val-(Nalpha-octa-2,4,6-trienoyl-L-Orn)]|sclerotiotide A

C22H34N4O4 (418.258)

celerioside E|eudesmane-1beta,4alpha,11-triol 11-O-beta-D-glucopyranoside

C21H38O8 (418.2567)

19-dimethylarsinoyl-nonadecanoic acid

C21H43AsO3 (418.2428)

eudesman-3,4alpha,11-triol-11-O-beta-D-glucopyranoside

C21H38O8 (418.2567)

scutione

C28H34O3 (418.2508)

(2E,6E)-10-beta-D-glucopyranosyl-1,10,11-trihydroxy-3,7,11-trimethyldodeca-2,6-diene

C21H38O8 (418.2567)

JBIR-15

C22H34N4O4 (418.258)

C22H34N4O4_N-Methyl-N-[(2E,4E,6E)-2,4,6-octatrienoyl]valylalanylprolinamide

NCGC00385036-01_C22H34N4O4_N-Methyl-N-[(2E,4E,6E)-2,4,6-octatrienoyl]valylalanylprolinamide

C22H34N4O4 (418.258)

Gly Lys Lys Ser

(2S)-2-[(2S)-6-amino-2-[(2S)-6-amino-2-(2-aminoacetamido)hexanamido]hexanamido]-3-hydroxypropanoic acid

C17H34N6O6 (418.254)

Gly Lys Ser Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-6-amino-2-(2-aminoacetamido)hexanamido]-3-hydroxypropanamido]hexanoic acid

C17H34N6O6 (418.254)

Gly Ser Lys Lys

(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-2-(2-aminoacetamido)-3-hydroxypropanamido]hexanamido]hexanoic acid

C17H34N6O6 (418.254)

Ile Ile Ser Ser

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-methylpentanamido]-3-hydroxypropanamido]-3-hydroxypropanoic acid